The FDA issued Guilford Pharmaceuticals Inc. approval to expand the use of the Gliadel Wafer as a first-line therapy for patients with high-grade malignant glioma. (BioWorld Today)

QLT Inc. agreed to temporarily suspend enrollment in two Phase III studies of tariquidar in non-small-cell lung cancer patients on advice of a monitoring committee, which reportedly noted some toxicity in the study. (BioWorld Today)

QLT Inc. agreed to temporarily suspend enrollment in two Phase III studies of tariquidar in non-small-cell lung cancer patients on advice of a monitoring committee, which reportedly noted some toxicity in the study. (BioWorld Today)